Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
- Buyers
- Keensight Capital, Symeres management
- Targets
- Symeres
- Sellers
- Gilde Healthcare
- Industry
- Healthcare Services
- Location
- Groningen, Netherlands
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Symeres Acquires DGr Pharma
September 15, 2025
Healthcare Services
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
-
Symeres Acquires Oncolines
January 10, 2023
Healthcare Services
Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.
-
Keensight Capital Acquires Majority Stake in Biovian
May 23, 2018
Biotechnology
Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.
-
Symeres Acquires Organix Inc.
April 26, 2022
Biotechnology
Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.
-
Keensight Capital Invests in CatSci Ltd
January 15, 2022
Healthcare Services
Keensight Capital has made a growth investment in CatSci Ltd, a Cardiff‑headquartered Contract Research Organisation (CRO) formed as a 2010 spin‑out from AstraZeneca. Keensight will invest alongside CatSci founders, senior management and employees to support the company's continued growth and capability expansion in small‑molecule and oligonucleotide CMC development and scale‑up.
-
Symeres Acquires Exemplify BioPharma
October 25, 2022
Pharmaceuticals
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.